Chugai Pharmaceutical Co., Ltd.4519
▼ ネガティブ技術関連度
Roche halted development of emugrobart for obesity, and Chugai gets the licensing rights returned, hitting its shares to a year-to-date low.
資産への影響 3
Biotech & Genomic Medicine
Chugai Pharmaceutical Co., Ltd.Consumer Discretionary
Happinet Corporation7552
▲ ポジティブ資本関連度
Happinet sharply raised its H1 operating profit forecast from 7.8bn to 13.5bn yen, a 55% YoY increase.
Health Care
Roche Holding AGROP
▼ ネガティブ技術関連度
Roche announced it is halting development of the anti-latent myostatin-sweeping antibody emugrobart for obesity.